ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,653,875 | -43.5% | 46,392 | -26.9% | 0.00% | 0.0% |
| Q2 2023 | $2,927,871 | -2.6% | 63,470 | -15.4% | 0.00% | 0.0% |
| Q1 2023 | $3,006,698 | -60.7% | 74,980 | -54.6% | 0.00% | -66.7% |
| Q4 2022 | $7,648,990 | +522.9% | 165,098 | +457.0% | 0.00% | +200.0% |
| Q3 2022 | $1,228,000 | -56.3% | 29,643 | -37.1% | 0.00% | 0.0% |
| Q2 2022 | $2,813,000 | -58.1% | 47,149 | -48.9% | 0.00% | -50.0% |
| Q1 2022 | $6,706,000 | +25.8% | 92,337 | +45.7% | 0.00% | 0.0% |
| Q4 2021 | $5,330,000 | +5.2% | 63,378 | +12.8% | 0.00% | 0.0% |
| Q3 2021 | $5,067,000 | +107.4% | 56,185 | +119.2% | 0.00% | +100.0% |
| Q2 2021 | $2,443,000 | -56.8% | 25,626 | -48.4% | 0.00% | -50.0% |
| Q1 2021 | $5,651,000 | +47.7% | 49,629 | +79.6% | 0.00% | +100.0% |
| Q4 2020 | $3,825,000 | +77.9% | 27,627 | +5.6% | 0.00% | 0.0% |
| Q3 2020 | $2,150,000 | -13.4% | 26,157 | -17.5% | 0.00% | 0.0% |
| Q2 2020 | $2,482,000 | -57.3% | 31,719 | -75.8% | 0.00% | -66.7% |
| Q1 2020 | $5,813,000 | +65.8% | 130,830 | +59.4% | 0.00% | +200.0% |
| Q4 2019 | $3,506,000 | -50.1% | 82,100 | -50.0% | 0.00% | -66.7% |
| Q3 2019 | $7,027,000 | +176.1% | 164,248 | +309.8% | 0.00% | +200.0% |
| Q2 2019 | $2,545,000 | +29.4% | 40,081 | +41.3% | 0.00% | 0.0% |
| Q1 2019 | $1,967,000 | -69.8% | 28,364 | -81.1% | 0.00% | -66.7% |
| Q4 2018 | $6,514,000 | +105.9% | 149,814 | +261.6% | 0.00% | +200.0% |
| Q3 2018 | $3,163,000 | +45.8% | 41,434 | +46.8% | 0.00% | 0.0% |
| Q2 2018 | $2,170,000 | -62.7% | 28,234 | -75.3% | 0.00% | -66.7% |
| Q1 2018 | $5,821,000 | +425.8% | 114,152 | +378.5% | 0.00% | – |
| Q4 2017 | $1,107,000 | -41.3% | 23,858 | -32.6% | 0.00% | -100.0% |
| Q3 2017 | $1,886,000 | +75.4% | 35,420 | +104.5% | 0.00% | 0.0% |
| Q2 2017 | $1,075,000 | +63.4% | 17,322 | +78.3% | 0.00% | – |
| Q1 2017 | $658,000 | -80.0% | 9,714 | -79.2% | 0.00% | -100.0% |
| Q4 2016 | $3,282,000 | +54.1% | 46,670 | +55.4% | 0.00% | +100.0% |
| Q3 2016 | $2,130,000 | +61.9% | 30,034 | +11.6% | 0.00% | 0.0% |
| Q2 2016 | $1,316,000 | +56.5% | 26,914 | +102.7% | 0.00% | 0.0% |
| Q1 2016 | $841,000 | -56.2% | 13,281 | -22.5% | 0.00% | 0.0% |
| Q4 2015 | $1,921,000 | +96.6% | 17,126 | +68.9% | 0.00% | 0.0% |
| Q3 2015 | $977,000 | -70.4% | 10,137 | -68.6% | 0.00% | -50.0% |
| Q2 2015 | $3,304,000 | +115.0% | 32,262 | +30.3% | 0.00% | +100.0% |
| Q1 2015 | $1,537,000 | +266.8% | 24,755 | +159.2% | 0.00% | – |
| Q4 2014 | $419,000 | – | 9,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |